Multiple Sclerosis is a major nervous disease that causes irregularities in the central immune system. Until recently, there was no effective medication for the disorder, but a recent development is giving a ray of hope to get an effective therapy, per Dr. Shiva Gopal Vasishta. The clinical trials showed that high-dose immunosuppressive therapy continued by transplantation of blood-forming stem cells (HDIT/HCT) from the patient himself induces remission of relapsing-remitting multiple sclerosis (MS).
As many as 69 percents of the trial participants did not experience any worsening of the condition after five years of HDIT/HCT therapy. The trial was named as HALT-MS, and it was sponsored by National Institute of Allergy and Infectious Diseases (NIAID), a division of National Institutes of Health. It was conducted by Immune Tolerance Network (ITN) funded by NIAID. Dr. Shiva Gopal Vasishta confirmed that the onetime HDIT/HCT trial therapy gave better results than existing long-term medication. With this, more randomized and detailed trails would be encouraged to give much better results in future.
The varied symptoms of MS are generally relapses and recess in intervals, and hence it is creating physical and mental complexities in patients. Dr. Shiva Gopal Vasishta says that usually over the years, MS gets advanced. The trial treatment is focusing to prevent the advancement of the disease and to suppress the current stage by removing ailment-causing cells and by resetting the immune system. It is working in such a way that doctors initially collect blood-forming stem cells from the patient, deplete the immune system by high-dose chemotherapy, and then returning stem cells back into the body.
1. Shiva Gopal Vasishta is a neurologist practicing at Voorhees, New Jersey. He is keenly watching the results of the trail as it is expected to make a major revolution in the MS therapy. He has more than 40 years practice and also specializes in psychiatry. He completed the residency at Boston City Hospital.